2 battered ASX growth shares that could double in value or more

MotleyFool

Mar 20

It's been a bruising start to 2026 for many ASX growth shares, with some among the biggest victims of this year's market onslaught. Two names that stand out are Mesoblast Ltd (ASX: MSB) and Zip Co Ltd...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2620275862"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620275862\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620275862?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 03:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620275862","market":"nz","top_or_hot":-1,"title":"2 battered ASX growth shares that could double in value or more","media":"MotleyFool","content":"<div>\n<p>It's been a bruising start to 2026 for many ASX growth shares, with some among the biggest victims of this year's market onslaught.\nTwo names that stand out are Mesoblast Ltd (ASX: MSB) and Zip Co Ltd...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/20/2-battered-asx-growth-shares-that-could-double-in-value-or-more/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 battered ASX growth shares that could double in value or more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 battered ASX growth shares that could double in value or more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-20 03:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2026/03/20/2-battered-asx-growth-shares-that-could-double-in-value-or-more/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's been a bruising start to 2026 for many ASX growth shares, with some among the biggest victims of this year's market onslaught.\nTwo names that stand out are Mesoblast Ltd (ASX: MSB) and Zip Co Ltd...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/20/2-battered-asx-growth-shares-that-could-double-in-value-or-more/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XJO.AU","symbol_name":"标普/澳交所 200指数","start_time":0,"source_url":"https://www.fool.com.au/2026/03/20/2-battered-asx-growth-shares-that-could-double-in-value-or-more/","article_id":"2620275862","we_media_id":null,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/20/2-battered-asx-growth-shares-that-could-double-in-value-or-more/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620275862","pubTimestamp":1773946800,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"It's been a bruising start to 2026 for many ASX growth shares, with some among the biggest victims of this year's market onslaught.Two names that stand out are Mesoblast Ltd  and Zip Co Ltd . At the time of writing, Mesoblast shares are down 23% year to date to $2.08, while Zip has plunged 52% to $1.48.By comparison theS&P/ASX 200 Indexhas shed 2.5% of its value so far this year.But after such steep declines for both ASX growth shares, could this be a classic buy the dip opportunity?This ASX growth share is no stranger to volatility, with its share price often swinging sharply on clinical updates and regulatory news.Even so, analysts remain optimistic on the ASX growth share, with an average 12-month price target of $4.23. This implies upside of around 104% from current levels.Rising interest rates, regulatory scrutiny, and concerns about consumer spending have all contributed to the sharp decline of the ASX growth share.After significant share price declines, they may be worth a close","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"XJO.AU":"标普/澳交所 200指数","MSB.AU":"MESOBLAST LTD","BK7093":"消费信贷","BK7067":"生物科技","ZIP.AU":"Zip Co Ltd","BK7508":"医药生物股","BK7501":"新冠治疗股"},"translate_title":"2只遭受重创的澳大利亚证券交易所成长型股票价值可能翻倍或更多","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XJO.AU":1,"ZIP.AU":1,"MSB.AU":1},"content_text":"It's been a bruising start to 2026 for many ASX growth shares, with some among the biggest victims of this year's market onslaught.\nTwo names that stand out are Mesoblast Ltd (ASX: MSB) and Zip Co Ltd (ASX: ZIP). At the time of writing, Mesoblast shares are down 23% year to date to $2.08, while Zip has plunged 52% to $1.48.\nBy comparison the S&P/ASX 200 Index (ASX: XJO) has shed 2.5% of its value so far this year.\nBut after such steep declines for both ASX growth shares, could this be a classic buy the dip opportunity?\nImage source: Getty Images\nMesoblast: High risk, high reward\nThis ASX growth share is no stranger to volatility, with its share price often swinging sharply on clinical updates and regulatory news.\nThe recent pullback reflects ongoing uncertainty around approvals and commercialisation timelines. They tend to weigh heavily on sentiment in the biotech sector.\nThat said, the company has a late-stage pipeline targeting inflammatory diseases, offering significant upside if key treatments are approved. Success could unlock major revenue opportunities and transform the business.\nThe biotech company has the potential for strong growth this year. Product adoption is increasing and the business is well funded to support its next phase of expansion.\nCommercial momentum is also improving. The latest quarterly update showed US$30 million in net revenue, supported by rising demand for its therapy Ryoncil in the United States.\nOf course, the risks are substantial — delays, setbacks, or funding pressures could hit the share price hard.\nEven so, analysts remain optimistic on the ASX growth share, with an average 12-month price target of $4.23. This implies upside of around 104% from current levels.\nZip: Turnaround story gaining traction?\nZip, on the other hand, has been caught in a broader sell-off across the buy now, pay later space.\nRising interest rates, regulatory scrutiny, and concerns about consumer spending have all contributed to the sharp decline of the ASX growth share.\nHowever, the company has been working to reposition itself, focusing on cost discipline and profitability, particularly in its core US market. If it can sustain margins while stabilising growth, the business could re-rate meaningfully.\nThe key risks remain tied to economic conditions and credit quality, as any deterioration could impact performance.\nStill, analysts are strikingly bullish, with an average price target of $4.21, suggesting potential upside of around 183%.\nFoolish Takeaway\nBoth Mesoblast and Zip highlight the trade-off at the heart of growth investing: elevated risk in exchange for potentially outsized returns. \nAfter significant share price declines, they may be worth a closer look for investors willing to ride the volatility.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}